Skip to content
Catalyst

paracetamolWhat was measured

Measured, with no finding

183 endpoints

Show what was measuredHide what was measured
  • Failure of ductal closure of a patent ductus arteriosus after paracetamol treatment versus ibuprofen, indomethacin, or placebo/no intervention, in preterm/low-birth-weight infants

    increases

    Not recorded as a finding: this platform holds no node for the endpoint

    Moderate-quality evidence according to GRADE suggests that paracetamol is as effective as ibuprofen; low-quality evidence suggests paracetamol to be more effective than placebo or no intervention; and low-quality evidence suggests paracetamol as effective as indomethacin in closing a PDA.

    PMID 31985831 · one of two readings recorded this

  • failure to close PDA, paracetamol vs indomethacin

    no effect

    There was no significant difference in the failure to close a PDA (typical RR 0.96, 95% CI 0.55 to 1.65; I² = 11%; typical RD -0.01, 95% CI -0.09 to 0.08; I² = 17%) (low quality of evidence).

    PMID 31985831 · one of two readings recorded this

  • Neurodevelopmental outcome at 18-24 months, vs ibuprofen

    no effect, n = 61

    There were no significant differences in the neurological outcomes at 18 to 24 months (n = 61); (low quality of evidence).

    PMID 31985831 · one of two readings recorded this

  • serum creatinine, paracetamol vs ibuprofen

    decreases

    The serum levels of creatinine were lower in the paracetamol group compared with the ibuprofen group in four studies (moderate quality of evidence), as were serum bilirubin levels following treatment in two studies (n = 290).

    PMID 31985831 · one of two readings recorded this

  • all-cause mortality and liver transplantation, N-acetylcysteine vs placebo, in non-paracetamol-induced acute liver failure

    no effect, RR 0.88, 95% CI 0.57 to 1.37 (adults, 21-day mortality)

    Not recorded as a finding: the paper never mentions the compound

    For all-cause mortality at 21 days between adults receiving N-acetylcysteine versus placebo, there was inconclusive evidence of effect (N-acetylcysteine 24/81 (29.6%) versus placebo 31/92 (33.7%); RR 0.88, 95% CI 0.57 to 1.37; low certainty evidence).

    PMID 33294991 · one of two readings recorded this

  • All-cause mortality at 21 days (adults) / one year (children)

    no effect

    For all-cause mortality at 21 days between adults receiving N-acetylcysteine versus placebo, there was inconclusive evidence of effect (N-acetylcysteine 24/81 (29.6%) versus placebo 31/92 (33.7%); RR 0.88, 95% CI 0.57 to 1.37; low certainty evidence).

    PMID 33294991 · one of two readings recorded this

  • all-cause mortality at 21 days, adults

    no effect, RR 0.88, 95% CI 0.57 to 1.37

    For all-cause mortality at 21 days between adults receiving N-acetylcysteine versus placebo, there was inconclusive evidence of effect (N-acetylcysteine 24/81 (29.6%) versus placebo 31/92 (33.7%); RR 0.88, 95% CI 0.57 to 1.37; low certainty evidence).

    PMID 33294991 · one of two readings recorded this

  • all-cause mortality at one year, children

    no effect, RR 1.47, 95% CI 0.85 to 2.53

    Similarly, for all-cause mortality at one year between children receiving N-acetylcysteine versus placebo, there was inconclusive evidence of effect (25/92 (27.2%) versus 17/92 (18.5%); RR 1.47, 95% CI 0.85 to 2.53; low certainty evidence).

    PMID 33294991 · one of two readings recorded this

  • Liver transplantation

    no effect

    For liver transplantation at 21 days in the trial with adults, there was inconclusive evidence of effect (RR 0.72, 95% CI 0.49 to 1.06; low certainty evidence).

    PMID 33294991 · one of two readings recorded this

  • Serious adverse events (children)

    no effect, RR 1.25, 95% CI 0.35 to 4.51

    There was inconclusive evidence of effect on serious adverse events in the trial with children (RR 1.25, 95% CI 0.35 to 4.51; low certainty evidence).

    PMID 33294991 · one of two readings recorded this

  • need for additional pain relief

    decreases, RR 0.34, 95% CI 0.21 to 0.55, n = 1132

    fewer women may need additional pain relief with paracetamol compared with placebo (average RR 0.34, 95% CI 0.21 to 0.55; 8 trials, 1132 women).

    PMID 34559424 · one of two readings recorded this

  • pain relief (SMD), exercise vs usual care

    increases

    For pain relief, exercise was more effective than usual care at or nearest to four (SMD=1.31, 95% CrI 0.61 to 2.01), eight (SMD=0.78, 95% CrI 0.58 to 0.98) and 24 weeks (SMD=0.19, 95% CrI 0.00 to 0.38).

    PMID 36593092 · one of two readings recorded this

  • Adverse events, paracetamol+NSAID combination

    no effect

    Paracetamol plus an NSAID did not increase the risk of AEs in low back pain or osteoarthritis compared to their NSAID monotherapy or placebo (comparison 1.6.1–1.6.5).

    PMID 38937394 · one of two readings recorded this

  • Adverse events, paracetamol+opioid combination

    increases

    Five out of the nine comparisons of paracetamol plus an opioid analgesic (tramadol or oxycodone) compared with placebo increased the risk of adverse events in low back pain and osteoarthritis (comparison 1.6.7, 1.6.8, 1.6.10, 1.6.11, 1.6.14).

    PMID 38937394 · one of two readings recorded this

  • adverse events, paracetamol plus opioid vs placebo

    increases

    Five out of the nine comparisons of paracetamol plus an opioid analgesic (tramadol or oxycodone) compared with placebo increased the risk of adverse events in low back pain and osteoarthritis (comparison 1.6.7, 1.6.8, 1.6.10, 1.6.11, 1.6.14).

    PMID 38937394 · one of two readings recorded this

  • disability score, low back pain, paracetamol plus ibuprofen vs ibuprofen, immediate term

    decreases, MD -9.2, 95% CI -16.8 to -1.6

    Paracetamol plus NSAID combination therapy improved disability scores in low back pain in one combination, paracetamol plus ibuprofen versus ibuprofen, immediate term (MD −9.2, 95% CI −16.8 to −1.6; one study; moderate evidence).

    PMID 38937394 · one of two readings recorded this

  • Disability scores

    decreases, MD -9.2, 95% CI -16.8 to -1.6 (paracetamol+ibuprofen vs ibuprofen, LBP, immediate term)

    Paracetamol plus NSAID combination therapy improved disability scores in low back pain in one combination, paracetamol plus ibuprofen versus ibuprofen, immediate term (MD −9.2, 95% CI −16.8 to −1.6; one study; moderate evidence).

    PMID 38937394 · one of two readings recorded this

  • Low back pain and osteoarthritis pain intensity on VAS/NRS/categorical pain scales, mean difference, by specific paracetamol combination versus monotherapy or placebo and timepoint

    decreases

    Not recorded as a finding: this platform holds no node for the endpoint

    Paracetamol plus tramadol reduced pain compared with placebo at intermediate term for low back pain (MD −11.7, 95% CI −19.2 to −4.3; two studies, very low evidence) and osteoarthritis (MD −6.8, 95% CI −12.7 to −0.9; one study, moderate evidence).

    PMID 38937394 · one of two readings recorded this

  • Pain intensity, paracetamol+tramadol vs placebo

    decreases, MD -11.7, 95% CI -19.2 to -4.3 (LBP, intermediate term); MD -6.8, 95% CI -12.7 to -0.9 (OA, intermediate term)

    Paracetamol plus tramadol reduced pain compared with placebo at intermediate term for low back pain (MD −11.7, 95% CI −19.2 to −4.3; two studies, very low evidence) and osteoarthritis (MD −6.8, 95% CI −12.7 to −0.9; one study, moderate evidence).

    PMID 38937394 · one of two readings recorded this

  • pain, low back pain and osteoarthritis, paracetamol plus tramadol vs placebo, intermediate term

    decreases, LBP: MD -11.7, 95% CI -19.2 to -4.3; OA: MD -6.8, 95% CI -12.7 to -0.9

    Paracetamol plus tramadol reduced pain compared with placebo at intermediate term for low back pain (MD −11.7, 95% CI −19.2 to −4.3; two studies, very low evidence) and osteoarthritis (MD −6.8, 95% CI −12.7 to −0.9; one study, moderate evidence).

    PMID 38937394 · one of two readings recorded this

  • quality of life (SF-36), paracetamol plus tramadol vs placebo

    no effect

    Paracetamol plus tramadol did not improve quality of life compared with placebo in low back pain or osteoarthritis populations (ESM).

    PMID 38937394 · one of two readings recorded this

  • Quality of life (SF-36)

    no effect

    Paracetamol plus tramadol did not improve quality of life compared with placebo in low back pain or osteoarthritis populations (ESM).

    PMID 38937394 · one of two readings recorded this

  • serious adverse events, paracetamol combination therapies vs individual controls

    no effect

    No combination therapy increased the risk of SAEs compared to individual controls (ESM).

    PMID 38937394 · one of two readings recorded this

  • mortality and transplant-free survival by acetaminophen exposure level (high, medium, low, none by history, serum level or APAP-CYS adducts) in viral hepatitis-associated acute liver failure

    no effect, high versus no exposure groups not statistically different after adjustment

    Not recorded as a finding: another reason, stated per paper

    However, the specific comparisons of mortality and transplant-free survival between the high exposure and no exposure groups were not statistically different even after adjusting for baseline patient characteristics differences.

    PMID 38994834 · one of two readings recorded this

  • mortality and transplant-free survival by acetaminophen exposure level (high, medium, low, none) in viral hepatitis-associated acute liver failure

    no effect, high versus no exposure groups not statistically different after adjustment

    Not recorded as a finding: the paper never states the instrument the node requires

    However, the specific comparisons of mortality and transplant-free survival between the high exposure and no exposure groups were not statistically different even after adjusting for baseline patient characteristics differences.

    PMID 38994834 · one of two readings recorded this

  • mortality and transplant-free survival, high versus no APAP exposure (adjusted)

    no effect, n = 356

    the specific comparisons of mortality and transplant-free survival between the high exposure and no exposure groups were not statistically different even after adjusting for baseline patient characteristics differences

    PMID 38994834 · one of two readings recorded this

  • mortality

    increases, n = 356

    Mortality was the highest (51.6%, 21.4%, 28.8%, and 30.5%), and transplant-free survival was the lowest (22.6%, 44.6%, 41.5%, and 40.4%) in the high exposure group compared with medium, low, and no exposure groups

    PMID 38994834 · one of two readings recorded this

  • patients with evidence of APAP use among AVH-ALF

    n = 356

    Two hundred five of 356 patients (57.5%) with AVH-ALF had evidence of APAP use

    PMID 38994834 · one of two readings recorded this

  • patients with high or medium APAP exposure

    n = 356

    87 out of 356 (24%) demonstrated high or medium exposures

    PMID 38994834 · one of two readings recorded this

  • transplant-free survival

    decreases, n = 356

    Mortality was the highest (51.6%, 21.4%, 28.8%, and 30.5%), and transplant-free survival was the lowest (22.6%, 44.6%, 41.5%, and 40.4%) in the high exposure group compared with medium, low, and no exposure groups

    PMID 38994834 · one of two readings recorded this

  • paracetamol exposure with higher body weight in SMA (simulation)

    increases

    Simulations revealed that in SMA patients, higher bodyweight was associated with increased exposure to paracetamol and its metabolites

    PMID 40040359 · one of two readings recorded this

  • hospital length of stay

    no effect, p = 0.6, n = 38

    Hospital length of stay, median (IQR), days | 19 (13–27) | 19 (13–23) | 18 (13–31) | 0.6

    PMID 40974583 · one of two readings recorded this

  • duration of mechanical ventilation

    no effect, p = 0.085, n = 38

    Duration of MV, median (IQR), h | 326 (223–383) | 250 (160–370) | 339 (233–470) | 0.085

    PMID 40974583 · one of two readings recorded this

  • albumin rate of change

    no effect, p = 0.75

    Both cohorts exhibited pronounced hypoalbuminemia from baseline, which worsened over time, with similar rates of change (p = 0.75)

    PMID 40974583 · one of two readings recorded this

  • arterial pH during CRRT

    decreases, p = 0.018

    the Phoxilium® group experienced a significant decrease in median arterial pH and standard base excess, remaining within normal limits, but lower than the Accusol® group (p = 0.018 and p = 0.046, respectively)

    PMID 40974583 · one of two readings recorded this

  • baseline age

    p = 0.012, n = 38

    Age, median (IQR), years | 40 (28–48) | 29 (27–38) | 45 (38–52) | 0.012

    PMID 40974583 · one of two readings recorded this

  • baseline arterial pH

    p = 0.042, n = 38

    Arterial pH, median (IQR) | 7.39 (7.32 to 7.45) | 7.45 (7.39 to 7.46) | 7.35 (7.30 to 7.42) | 0.042

    PMID 40974583 · one of two readings recorded this

  • baseline base excess

    p = 0.014, n = 38

    Base excess, median (IQR), mmol/L | −5.1 (−9.2 to −0.4) | −0.5 (−4.8 to 1.7) | −7.1 (−9.7 to −2.8) | 0.014

    PMID 40974583 · one of two readings recorded this

  • baseline bicarbonate

    p = 0.02, n = 38

    Bicarbonate, median (IQR), mmol/L | 19.0 (15.3 to 23.0) | 22.5 (19.0 to 25.0) | 17.0 (14.8 to 21.0) | 0.020

    PMID 40974583 · one of two readings recorded this

  • baseline INR

    no effect, p = 0.86, n = 38

    INR, median (IQR) | 4.45 (3.10 to 6.08) | 4.40 (2.98 to 5.43) | 4.60 (3.10 to 6.28) | 0.86

    PMID 40974583 · one of two readings recorded this

  • baseline ionised calcium

    no effect, p = 0.082, n = 38

    Ionised calcium, median (IQR), mmol/L | 1.12 (1.04 to 1.16) | 1.13 (1.10 to 1.19) | 1.09 (1.00 to 1.15) | 0.082

    PMID 40974583 · one of two readings recorded this

  • baseline lactate

    no effect, p = 0.14, n = 38

    Lactate, median (IQR), mmol/L | 3.9 (2.6 to 8.1) | 3.2 (2.3 to 4.8) | 5.0 (3.0 to 10.5) | 0.14

    PMID 40974583 · one of two readings recorded this

  • baseline peak ammonia

    no effect, p = 0.86, n = 38

    Peak ammonia, median (IQR), mmol/L | 240 (151 to 335) | 258 (152 to 284) | 212 (107 to 347) | 0.86

    PMID 40974583 · one of two readings recorded this

  • baseline serum phosphate

    no effect, p = 0.27, n = 38

    Phosphate, median (IQR), mmol/L | 0.97 (0.66 to 1.22) | 0.74 (0.65 to 1.15) | 1.11 (0.80 to 1.25) | 0.27

    PMID 40974583 · one of two readings recorded this

  • burden of hypophosphataemia (proportion of phosphate readings below threshold)

    decreases, p = 0.001, n = 38

    Burden of hypophosphataemiaa, median (IQR), % | 33 (20–50) | 13 (2–33) | 44 (29–51) | 0.001

    PMID 40974583 · one of two readings recorded this

  • CRRT effluent dose

    no effect, p = 0.21, n = 38

    Effluent dose, median (IQR), mL/kg/h | 45 (39–63) | 54 (41–72) | 43 (38–56) | 0.21

    PMID 40974583 · one of two readings recorded this

  • cumulative phosphate supplementation dose (mixed model reading)

    decreases, p = 0.011

    patients in the Accusol® group required more phosphate supplementation, with a median cumulative dose of 100 (35–180) mmol compared to 45 (20–70) mmol in the Phoxilium® group (p = 0.011)

    PMID 40974583 · one of two readings recorded this

  • delivered versus prescribed CRRT dose

    increases, p = 0.019, n = 38

    Delivered vs. prescribed dose, % (IQR) | 94.3 (92.6–96.5) | 96.0 (94.4–96.6) | 93.3 (91.6–95.7) | 0.019

    PMID 40974583 · one of two readings recorded this

  • hospital mortality

    no effect, p = 0.6, n = 38

    Hospital mortality, n (%) | 4 (11) | 2 (14) | 2 (8·3) | 0.6

    PMID 40974583 · one of two readings recorded this

  • ICU length of stay

    no effect, p = 0.24, n = 38

    ICU length of stay, median (IQR), days | 13 (7–19) | 13 (9–16) | 13 (6–20) | 0.24

    PMID 40974583 · one of two readings recorded this

  • ICU mortality adjusted for APACHE III

    no effect, p = 0.5, n = 38

    After adjusting for APACHE III scores, Phoxilium® was not associated with reduced ICU mortality (odds ratio, 0.47 [95% CI: 0.05–4.48]; p = 0.50)

    PMID 40974583 · one of two readings recorded this

  • ICU mortality

    no effect, p = 0.6, n = 38

    ICU mortality, n (%) | 4 (11) | 2 (14) | 2 (8·3) | 0.6

    PMID 40974583 · one of two readings recorded this

  • incident hypophosphataemia

    decreases, p = 0.001, n = 38

    Incident hypophosphataemia, n (%) | 32 (84) | 8 (57) | 24 (100) | 0.001

    PMID 40974583 · one of two readings recorded this

  • incident severe hypophosphataemia (phosphate <0.32 mmol/L) within 168 h

    decreases, p = 0.014, n = 38

    Incident severe hypophosphataemia, n (%) | 9 (24) | 0 (0) | 9 (38) | 0.014

    PMID 40974583 · one of two readings recorded this

  • ionised calcium over first 72 h

    decreases, p = 0.001

    Over the first 72 h, median ionised calcium in the Accusol® group rapidly increased and stabilised around 1.3 mmol/L, while the Phoxilium® group maintained lower levels (p < 0.001)

    PMID 40974583 · one of two readings recorded this

  • lactate at baseline

    decreases, p = 0.001

    Lactate concentrations were higher at baseline in the Accusol® group (p < 0.001)

    PMID 40974583 · one of two readings recorded this

  • peak ALT at baseline

    no effect, p = 0.82, n = 38

    Peak ALT, median (IQR), IU | 6,495 (4,088 to 10,602) | 6,838 (4,966 to 8,938) | 6,338 (3,744 to 11,655) | 0.82

    PMID 40974583 · one of two readings recorded this

  • peak GGT at baseline

    decreases, p = 0.046, n = 38

    Peak GGT, median (IQR), IU | 120 (74 to 222) | 90 (41 to 161) | 135 (101 to 240) | 0.046

    PMID 40974583 · one of two readings recorded this

  • phosphate level change rate, fluid type by time interaction

    increases, p = 0.001

    A significant interaction between fluid type and time (p < 0.001) indicated differing rates of phosphate level changes, with the Phoxilium® group improving more rapidly

    PMID 40974583 · one of two readings recorded this

  • phosphate supplementation

    decreases, p = 0.008, n = 38

    Phosphate supplementation, median (IQR), mmol | 80 (40–190) | 45 (20–70) | 100 (60–210) | 0.008

    PMID 40974583 · one of two readings recorded this

  • rate of change in ionised calcium, fluid type by time interaction

    no effect, p = 0.232

    the rate of change in ionised calcium did not differ significantly (interaction p = 0.232)

    PMID 40974583 · one of two readings recorded this

  • serum phosphate after CRRT initiation, Accusol® group

    decreases, p = 0.001, n = 24

    The Accusol® group experienced a decline in median phosphate levels from 1.11 (0.80–1.25) to 0.62 (0.54–0.78) mmol/L after 12–18 h, remaining significantly lower than the Phoxilium® group throughout the study period (p < 0.001)

    PMID 40974583 · one of two readings recorded this

  • serum phosphate after CRRT initiation, Phoxilium® group

    increases, n = 14

    In contrast, the Phoxilium® group experienced an increase from 0.74 (0.65–1.15) to 1.09 (0.94–1.20) mmol/L

    PMID 40974583 · one of two readings recorded this

  • standard base excess during CRRT

    decreases, p = 0.046

    the Phoxilium® group experienced a significant decrease in median arterial pH and standard base excess, remaining within normal limits, but lower than the Accusol® group (p = 0.018 and p = 0.046, respectively)

    PMID 40974583 · one of two readings recorded this

  • total CRRT duration

    no effect, p = 0.24, n = 38

    Total CRRT durationc, median (IQR), h | 153 (96–157) | 155 (127–162) | 149 (83–156) | 0.24

    PMID 40974583 · one of two readings recorded this

  • transplant-free survival

    no effect, p = 0.99, n = 38

    Transplant-free survival, n (%) | 32 (84) | 12 (86) | 20 (83) | 0.99

    PMID 40974583 · one of two readings recorded this

  • body mass index

    no effect, p = 0.239

    Body mass index (kg/m2) | 21 (19–26) | 23 (21–27) | 24 (20–26) | 0.239

    PMID 40990326 · one of two readings recorded this

  • age

    no effect, p = 0.334

    Age (years) | 23 (21–42) | 34 (22–57) | 26 (20–47) | 0.334

    PMID 40990326 · one of two readings recorded this

  • change in half-life, first to second

    decreases, p = 0.001, n = 71

    First–second | −1.9 (−3.5–−1.0) | 71 | −4.9 (−8.7 to −2.5) † | 26 | −1.8 (−2.0 to −1.1) † | 20 | −1.1 (−1.9 to −0.4) † | 25 | <0.001

    PMID 40990326 · one of two readings recorded this

  • deceased, n (%)

    p = 0.094

    Deceased; n (%) | 3 (12) | 0 (0) | 0 (0) | 0.094 †

    PMID 40990326 · one of two readings recorded this

  • first half-life

    p = 0.001, n = 71

    First | 4.6 (3.5–8.2) | 71 | 9.3 (7.8–11.7) | 26 | 4.5 (4.2–4.8) | 20 | 3.0 (2.4–3.6) | 25 | <0.001

    PMID 40990326 · one of two readings recorded this

  • first paracetamol concentration

    no effect, p = 0.52

    First paracetamol concentration (mg/L) | 185 (143–326) | 185 (129–242) | 172 (142–209) | 0.520

    PMID 40990326 · one of two readings recorded this

  • fourth half-life

    n = 4

    Fourth | 2.0 (1.9–8.9) | 4 | 2.0 (1.9–8.9) | 4 | — | 0 | — | 0 | —

    PMID 40990326 · one of two readings recorded this

  • ingested dose per bodyweight

    no effect, p = 0.243

    Ingested dose per bodyweight (mg/kg) | 463 (300–655) | 340 (218–667) | 326 (267–417) | 0.243

    PMID 40990326 · one of two readings recorded this

  • ingested dose

    no effect, p = 0.318

    Ingested dose (g) | 28 (18–50) | 22 (15–50) | 23 (18–28) | 0.318

    PMID 40990326 · one of two readings recorded this

  • paracetamol concentration, sample 1

    no effect, p = 0.52, n = 71

    Sample 1 | 175 (142–248) | 71 | 185 (143–326) | 26 | 185 (129–242) | 20 | 172 (142–209) | 25 | 0.520

    PMID 40990326 · one of two readings recorded this

  • paracetamol concentration, sample 2

    p = 0.001, n = 71

    Sample 2 | 70 (46–103) | 71 | 97 (70–198) | 26 | 64 (43–101) | 20 | 51 (24–75) | 25 | <0.001

    PMID 40990326 · one of two readings recorded this

  • paracetamol concentration, sample 3

    p = 0.001, n = 71

    Sample 3 | 7.7 (0.1–23) | 71 | 26 (13–52) | 26 | 7 (5–15) | 20 | 0.1 (0.1–5) | 25 | <0.001

    PMID 40990326 · one of two readings recorded this

  • paracetamol concentration, sample 4

    p = 0.224, n = 18

    Sample 4 | 6.6 (0.1–18) | 18 | 8.1 (5.3–28) | 13 | 0.1 (0.1–5) | 4 | 6.4 | 1 | 0.224

    PMID 40990326 · one of two readings recorded this

  • paracetamol concentration, sample 5

    n = 4

    Sample 5 | 0.1 (0.1–7.0) | 4 | 0.1 (0.1–7.0) | 4 | — | 0 | — | 0 | —

    PMID 40990326 · one of two readings recorded this

  • paracetamol elimination half-life after acute overdose during acetylcysteine treatment, calculated as Ln 2 over the elimination constant from consecutive plasma concentrations, first versus second half-life

    decreases, first half-life 4.6 (3.5-8.2) h to second half-life 2.9 (2.1-3.8) h, within-patient, n = 71

    Not recorded as a finding: this platform holds no node for the endpoint

    The half-life changed from 4.6 (3.5–8.2) h for the first half-life to 2.9 (2.1–3.8) h for the second half-life (P < 0.001).

    PMID 40990326 · one of two readings recorded this

  • paracetamol half-life, first versus second half-life

    decreases, p = 0.001, n = 71

    The half-life changed from 4.6 (3.5–8.2) h for the first half-life to 2.9 (2.1–3.8) h for the second half-life (P < 0.001)

    PMID 40990326 · one of two readings recorded this

  • paracetamol plasma half-life, first versus second consecutive half-life after acute overdose in acetylcysteine-treated patients

    decreases, median half-life 4.6 (3.5-8.2) h first versus 2.9 (2.1-3.8) h second

    Not recorded as a finding: the compound is what was measured, not what was given

    The half-life changed from 4.6 (3.5–8.2) h for the first half-life to 2.9 (2.1–3.8) h for the second half-life (P < 0.001).

    PMID 40990326 · one of two readings recorded this

  • peak ALT >1000 IU/L, n (%)

    p = 0.071

    Peak ALT >1000 IU/L; n (%) | 3 (12) | 0 (0) | 0 (0) | 0.071 †

    PMID 40990326 · one of two readings recorded this

  • second half-life

    p = 0.001, n = 71

    Second | 2.9 (2.1–3.8) | 71 | 4.5 (3.2–5.4) | 26 | 3.0 (2.5–3.6) | 20 | 2.0 (1.2–2.4) | 25 | <0.001

    PMID 40990326 · one of two readings recorded this

  • third half-life

    p = 0.104, n = 18

    Third | 3.9 (2.3–6.2) | 18 | 6.0 (3.7–6.7) | 13 | 1.7 (0.9–3.1) | 4 | 2.3 | 1 | 0.104

    PMID 40990326 · one of two readings recorded this

  • time between samples 1-2

    no effect, p = 0.195, n = 71

    Between samples 1-2 | 5.6 (4.0–9.5) | 71 | 6.8 (4.1–11.0) | 26 | 5.1 (4.0–9.1) | 20 | 4.4 (4.0–7.4) | 25 | 0.195

    PMID 40990326 · one of two readings recorded this

  • time between samples 2-3

    no effect, p = 0.369, n = 71

    Between samples 2-3 | 9.0 (6.4–12.9) | 71 | 8.9 (6.4–11.0) | 26 | 8.5 (6.4–10.4) | 20 | 11.8 (7.0–14.2) | 25 | 0.369

    PMID 40990326 · one of two readings recorded this

  • time between samples 3-4

    no effect, p = 0.203, n = 18

    Between samples 3-4 | 13.3 (6.4–19.3) | 18 | 16.5 (8.3–24.0) | 13 | 7.4 (6.8–12.8) | 4 | 4.2 | 1 | 0.203

    PMID 40990326 · one of two readings recorded this

  • time between samples 4-5

    n = 4

    Between samples 4-5 | 15.9 (15.3–19.6) | 4 | 15.9 (15.3–19.6) | 4 | — | 0 | — | 0 | —

    PMID 40990326 · one of two readings recorded this

  • time to acetylcysteine after ingestion

    no effect, p = 0.666

    Time to acetylcysteine after ingestion (h) | 4.0 (2.3–7.5) | 5.4 (3.0–6.5) | 4.2 (2.5–6.0) | 0.666

    PMID 40990326 · one of two readings recorded this

  • time to first concentration after ingestion

    no effect, p = 0.919

    Time to first concentration after ingestion (h) | 4.0 (4.0–5.1) | 4.0 (3.8–5.3) | 4.0 (3.9–4.5) | 0.919

    PMID 40990326 · one of two readings recorded this

  • change in NRS

    decreases, n = 1241

    Change in NRS [Mean ± SD] | 3.9 ± 2.0 | 2.9 ± 2.0 | 4.6 ± 2.1 | 4.0 ± 1.5

    PMID 41039602 · one of two readings recorded this

  • drug-related complications, odds by age

    increases, p = 0.0109, n = 1241

    Age | 1.02 | 1.00‒ 1.03 | 0.0109

    PMID 41039602 · one of two readings recorded this

  • drug-related complications, odds by sex

    no effect, p = 0.0863, n = 1241

    Sex (female vs. male) | 1.67 | 0.93‒3.00 | 0.0863

    PMID 41039602 · one of two readings recorded this

  • drug-related complications, odds, nalbuphine + paracetamol versus piritramide

    no effect, p = 0.3, n = 1241

    the comparison of nalbuphine plus paracetamol vs. piritramide showed no evidence for a difference (OR: 0.75, 95% CI: 0.45–1.24, p = 0.3)

    PMID 41039602 · one of two readings recorded this

  • drug-related complications, odds, paracetamol versus nalbuphine + paracetamol

    decreases, p = 0.01, n = 1241

    While the comparison of paracetamol vs. nalbuphine plus paracetamol showed lower odds of complications during treatment (OR: 0.17, 95% CI: 0.06–0.49, p < 0.01)

    PMID 41039602 · one of two readings recorded this

  • effective analgesia (NRS ≤ 4 at hospital admission), odds

    increases, p = 0.01, n = 1241

    While treatment with nalbuphine plus paracetamol increased the odds of achieving NRS ≤ 4 at hospital admission (OR: 3.25, 95% CI: 2.46–4.30, p < 0.01)

    PMID 41039602 · one of two readings recorded this

  • effective analgesia (NRS ≤ 4 at hospital admission), odds

    decreases, p = 0.0001, n = 1241

    Paracetamol vs. nalbuphine + paracetamol | 0.32 | 0.23‒ 0.45 | < 0.0001

    PMID 41039602 · one of two readings recorded this

  • effective analgesia (NRS ≤ 4 at hospital admission), odds

    decreases, p = 0.0001, n = 1241

    Piritramide vs. nalbuphine + paracetamol | 0.31 | 0.23‒ 0.41 | < 0.0001

    PMID 41039602 · one of two readings recorded this

  • effective analgesia (NRS ≤ 4), odds by age

    no effect, p = 0.7565, n = 1241

    Age | 1.00 | 1.00‒1.01 | 0.7565

    PMID 41039602 · one of two readings recorded this

  • effective analgesia (NRS ≤ 4), odds by sex

    no effect, p = 0.8395, n = 1241

    Sex (female vs. male) | 1.03 | 0.79‒1.33 | 0.8395

    PMID 41039602 · one of two readings recorded this

  • effective analgesia (NRS ≤ 4), odds per initial NRS point

    decreases, p = 0.0001, n = 1241

    Initial numeric rating scale | 0.66 | 0.60‒ 0.73 | < 0.0001

    PMID 41039602 · one of two readings recorded this

  • effective analgesia, numeric rating scale score of 4 or less at hospital admission, intravenous paracetamol versus nalbuphine plus paracetamol versus piritramide, logistic regression

    decreases, paracetamol versus nalbuphine plus paracetamol, OR 0.32, 95% CI 0.23-0.45

    Not recorded as a finding: the comparison was against another active treatment

    While treatment with nalbuphine plus paracetamol increased the odds of achieving NRS ≤ 4 at hospital admission (OR: 3.25, 95% CI: 2.46–4.30, p < 0.01), treatment with piritramide (OR: 0.31, 95% CI: 0.23–0.41, p < 0.01) or paracetamol (OR: 0.32, 95% CI: 0.23–0.45, p < 0.01) reduced this chance.

    PMID 41039602 · one of two readings recorded this

  • initial NRS

    n = 1241

    NRS initial [Mean ± SD] | 7.9 ± 1.4 | 6.8 ± 1.4 | 8.2 ± 1.3 | 8.3 ± 1.1

    PMID 41039602 · one of two readings recorded this

  • NRS at hospital admission

    n = 1241

    NRS hospital admission [Mean ± SD] | 4.0 ± 1.8 | 4.0 ± 1.9 | 3.6 ± 1.9 | 4.3 ± 1.5

    PMID 41039602 · one of two readings recorded this

  • patients achieving NRS ≤ 4 at hospital admission

    n = 1241

    nalbuphine + paracetamol: n = 236 [47.5%]; piritramide: n = 142 [28.6%]; paracetamol: n = 119 [23.9%]

    PMID 41039602 · one of two readings recorded this

  • patients with NRS reduction ∆NRS < 2

    n = 439

    Nalbuphine + paracetamol | 29 (6.6%) | 24 (5.5%) | 61 (13.9%) | 91 (20.7%) | 234 (53.5%)

    PMID 41039602 · one of two readings recorded this

  • patients with NRS reduction ∆NRS < 2

    n = 291

    Paracetamol | 66 (22.7%) | 71 (24.4%) | 61 (21.0%) | 40 (13.7%) | 53 (18.2%)

    PMID 41039602 · one of two readings recorded this

  • patients with NRS reduction ∆NRS < 2

    n = 511

    Pritramide | 22 (4.3%) | 62 (12.1%) | 102 (20.0%) | 148 (29.0%) | 177 (34.6%)

    PMID 41039602 · one of two readings recorded this

  • patients with NRS reduction ∆NRS > 4

    n = 439

    Nalbuphine + paracetamol | 29 (6.6%) | 24 (5.5%) | 61 (13.9%) | 91 (20.7%) | 234 (53.5%)

    PMID 41039602 · one of two readings recorded this

  • patients with NRS reduction ∆NRS > 4

    n = 291

    Paracetamol | 66 (22.7%) | 71 (24.4%) | 61 (21.0%) | 40 (13.7%) | 53 (18.2%)

    PMID 41039602 · one of two readings recorded this

  • patients with NRS reduction ∆NRS > 4

    n = 511

    Pritramide | 22 (4.3%) | 62 (12.1%) | 102 (20.0%) | 148 (29.0%) | 177 (34.6%)

    PMID 41039602 · one of two readings recorded this

  • total dose of nalbuphine

    n = 439

    Total dose of nalbuphine (mg) [Mean ± SD] | 14.2 ± 5.9 | - | 14.2 ± 5.9 | -

    PMID 41039602 · one of two readings recorded this

  • total dose of paracetamol

    n = 730

    Total dose of paracetamol (mg) [Mean ± SD] | 996.1 ± 45.5 | 994.3 ± 49.6 | 997.3 ± 42.7 | -

    PMID 41039602 · one of two readings recorded this

  • total dose of piritramide

    n = 511

    Total dose of piritramide (mg) [Mean ± SD] | 7.1 ± 3.5 | - | - | 7.1 ± 3.5

    PMID 41039602 · one of two readings recorded this

  • Correlation of miR-122 with ALT

    increases, p = 0.03

    miR-122 moderately correlated with ALT (r = 0.56, p = 0.03)

    PMID 41248904 · one of two readings recorded this

  • miR-122 ROC area under the curve for paracetamol DILI

    n = 38

    ROC analysis yielded an area under the curve (AUC) of 0.96

    PMID 41248904 · one of two readings recorded this

  • miR-122 sensitivity at 29.7 pg/mL cut-off

    n = 38

    92.6% sensitivity (95% CI: 76.6%-98.7%)

    PMID 41248904 · one of two readings recorded this

  • miR-122 specificity at 29.7 pg/mL cut-off

    n = 38

    89.4% specificity (95% CI: 68.6%-98.1%)

    PMID 41248904 · one of two readings recorded this

  • Serum miR-122 concentration

    increases, n = 38

    The median miR-122 concentration was significantly elevated at 233.4 pg/mL (IQR: 74.5-363.4) compared to 15.2 pg/mL (IQR: 9.4-24) in the control group

    PMID 41248904 · one of two readings recorded this

  • Serum miR-122 group difference (Mann-Whitney U test)

    increases, p = 0.0001, n = 38

    The Mann-Whitney U test showed significant group differences (p < 0.0001)

    PMID 41248904 · one of two readings recorded this

  • All childhood cancers

    no effect, n = 2754

    The main analysis did not yield sufficient evidence to conclude that acetaminophen exposure during pregnancy increases the risk of all childhood cancers

    PMID 41342591 · one of two readings recorded this

  • Childhood bone tumors

    unclear

    bone tumors (adjusted HR = 1.85; 95% CI, 0.92-3.72)

    PMID 41342591 · one of two readings recorded this

  • Childhood hepatoblastoma

    unclear

    hepatoblastoma (adjusted HR = 1.73; 95% CI, 0.97-3.10)

    PMID 41342591 · one of two readings recorded this

  • Childhood medulloblastoma

    increases

    medulloblastoma [adjusted hazard ratio (HR) = 2.43; 95% confidence interval (CI), 1.10-5.39]

    PMID 41342591 · one of two readings recorded this

  • alanine aminotransferase

    no effect, p = 0.938, n = 194

    Alanine aminotransferase (IU/L)b | 14 (10–21) | 14 (10–20) | 14 (9–28) | 17 (10–27) | 0.938

    PMID 41456031 · one of two readings recorded this

  • serum albumin

    decreases, p = 0.011, n = 194

    Albumin (g/dL) | 4.5 (4.2–4.8) | 4.6 (4.3–4.8) | 4.3(3.8–4.6) | 4.1 (3.7–4.5) | 0.011c

    PMID 41456031 · one of two readings recorded this

  • age

    no effect, p = 0.137, n = 194

    Age (year) | 21 (17–32) | 21 (17-32.5) | 23 (18–31) | 16 (15–31) | 0.137

    PMID 41456031 · one of two readings recorded this

  • AUC of elapsed time for predicting toxic APAP concentration after 15 h

    p = 0.001

    The AUC for predicting toxic APAP concentration 15 h after ingestion using elapsed time was 0.969 (95% CI 0.934–0.989, p < 0.001)

    PMID 41456031 · one of two readings recorded this

  • body weight

    no effect, p = 0.689, n = 194

    Weight (kg) | 56.0 (50.0–65.0) | 56.0 (50.0-64.5) | 57.0 (48.0–65.0) | 54 (43–66) | 0.689

    PMID 41456031 · one of two readings recorded this

  • elevated liver enzyme, n (%)

    no effect, p = 0.132, n = 194

    Elevated liver enzyme | 15 (7.7) | 9 (5.7) | 6 (20.0) | 0 (0.0) | 0.132

    PMID 41456031 · one of two readings recorded this

  • ingested dose per kilogram of weight

    no effect, p = 0.07, n = 194

    Ingested dose per kilogram of weight (mg/kg) | 152.8 (100.0-234.0) | 150.0 (91.6-222.2) | 177.7 (132.3–350.0) | 166.6 (138.8-190.4) | 0.070

    PMID 41456031 · one of two readings recorded this

  • male gender, n (%)

    no effect, p = 0.591, n = 194

    Gender, Male | 31 (16.0) | 25 (15.9) | 5 (16.7) | 1 (14.3) | 0.591

    PMID 41456031 · one of two readings recorded this

  • N-acetylcysteine treatment, n (%)

    no effect, p = 0.163, n = 194

    N-acetylcysteine treatment | 158 (81.4) | 125 (79.6) | 27 (90.0) | 6 (85.7) | 0.163

    PMID 41456031 · one of two readings recorded this

  • patients above the 100-treatment line at first APAP test

    showed concentrations above the 100-treatment line in the first APAP concentration test, with a median time from ingestion to the first test of 449 min

    PMID 41456031 · one of two readings recorded this

  • patients ingesting at least 10 g or 200 mg/kg APAP

    87 patients (44.8%) ingested at least 10 g or 200 mg/kg of APAP, and all received NAC treatment

    PMID 41456031 · one of two readings recorded this

  • patients with detectable or toxic serum APAP concentration after 15 h

    A total of 37 patients (19.0%) showed detectable and toxic serum APAP concentrations after 15 h of ingestion

    PMID 41456031 · one of two readings recorded this

  • sensitivity of 612 min cut-off for toxic APAP concentration after 15 h

    The sensitivity and specificity of 612 min cut-off value were 100.0% (95% CI 59.0-100.0) and 92.5% (95% CI 87.8–95.8)

    PMID 41456031 · one of two readings recorded this

  • specificity of 612 min cut-off for toxic APAP concentration after 15 h

    The sensitivity and specificity of 612 min cut-off value were 100.0% (95% CI 59.0-100.0) and 92.5% (95% CI 87.8–95.8)

    PMID 41456031 · one of two readings recorded this

  • time from ingestion to presentation as predictor of detectable APAP concentration after 15 h (vs undetected)

    no effect, p = 0.233

    Time from ingestion to presentation [log(minute)] | 1.322 (0.835–2.093) | 0.233 | 1908 (12-283373) | 0.003

    PMID 41456031 · one of two readings recorded this

  • time from ingestion to presentation as predictor of toxic APAP concentration after 15 h (vs undetected)

    increases, p = 0.003

    elapsed time from ingestion to EMC presentation was found to be a significant independent variable in predicting the toxic concentration 15 h after ingestion compared with the undetected serum levels (OR = 1908.536, 95% CI 12.854–283373.365, p = 0.003)

    PMID 41456031 · one of two readings recorded this

  • time from ingestion to presentation

    increases, p = 0.001, n = 194

    Time from ingestion to presentation (minute) | 218 (89–431) | 200 (82–380) | 239 (113–467) | 847 (669–871) | < 0.001c

    PMID 41456031 · one of two readings recorded this

  • total ingested dose

    no effect, p = 0.074, n = 194

    Total ingested dose (g) | 9.0 (5.6–13.0) | 8.8 (5.1–12.7) | 10.2 (8.0–22.0) | 8.0 (6.5–9.7) | 0.074

    PMID 41456031 · one of two readings recorded this

  • Cortical surface area and volume in some regions

    decreases, n = 193

    Vertex-wise linear mixed effect models showed that exposed children (n = 193; 393 scans) had slightly smaller cortical surface area and volume in some regions compared to non-exposed children

    PMID 41496292 · one of two readings recorded this

  • Cortical surface area and volume in some regions

    decreases, n = 21

    These results were seemingly driven by long-term exposed children (≥14 days in utero; n = 35; 72 scans, and exposed in all three trimesters, n = 21; 44 scans)

    PMID 41496292 · one of two readings recorded this

  • Cortical surface area and volume in some regions

    decreases, n = 35

    These results were seemingly driven by long-term exposed children (≥14 days in utero; n = 35; 72 scans, and exposed in all three trimesters, n = 21; 44 scans)

    PMID 41496292 · one of two readings recorded this

  • cortical surface area and volume on MRI, vertex-wise linear mixed effect models

    decreases, slightly smaller cortical surface area and volume in some regions

    Not recorded as a finding: no outcome node for cortical surface area or volume by MRI

    Vertex-wise linear mixed effect models showed that exposed children (n = 193; 393 scans) had slightly smaller cortical surface area and volume in some regions compared to non-exposed children.

    PMID 41496292 · one of two readings recorded this

  • Days of prenatal exposure

    n = 193

    Days of exposure range from 1 to 128 (mean 8.2)

    PMID 41496292 · one of two readings recorded this

  • Prenatal paracetamol exposure prevalence

    n = 447

    Among 447 children (229 girls; mean age 8.38 years), 193 (43.2 %) were prenatally exposed.

    PMID 41496292 · one of two readings recorded this

  • working memory capacity and IQ scores in children after prenatal paracetamol exposure; cortical surface area and volume on MRI

    no effect

    Not recorded as a finding: the paper never states the instrument the node requires

    For cognitive abilities, results were reassuring showing no significant effect of prenatal paracetamol exposure on working memory capacity or IQ scores.

    PMID 41496292 · one of two readings recorded this

  • Working memory capacity and IQ scores

    no effect

    For cognitive abilities, results were reassuring showing no significant effect of prenatal paracetamol exposure on working memory capacity or IQ scores

    PMID 41496292 · one of two readings recorded this

  • Accidental exposures (count of unintentional paracetamol exposures)

    n = 17318

    There were 17,318 unintentional paracetamol exposures including 10,189 dosing errors and 7129 accidental exposures.

    PMID 41803773 · one of two readings recorded this

  • Dosing errors (count of unintentional paracetamol exposures)

    n = 17318

    There were 17,318 unintentional paracetamol exposures including 10,189 dosing errors and 7129 accidental exposures.

    PMID 41803773 · one of two readings recorded this

  • Hepatotoxicity among hospitalised exposures

    n = 142

    No cases of liver transplantation or death were identified and only 3.0% (n = 2) developed hepatotoxicity.

    PMID 41803773 · one of two readings recorded this

  • Hospitalisation among 2021 in-depth exposures

    n = 1498

    In-depth analysis of exposures from 2021 was done on 1498 exposures (median age 1 year, 54.0% male) with 1.7% (n = 26) requiring hospitalisation.

    PMID 41803773 · one of two readings recorded this

  • N-acetylcysteine treatment among hospitalised exposures

    n = 142

    Of these, 10.6% (n = 15) were treated with the antidote, N-acetylcysteine.

    PMID 41803773 · one of two readings recorded this

  • Accidental ingestion proportion

    n = 197

    Accidental ingestion accounted for 49.2% of cases, whereas 50.8% were intentional.

    PMID 41998668 · one of two readings recorded this

  • Asymptomatic at presentation

    n = 197

    At presentation, 68.5% of patients were asymptomatic, and nausea and vomiting were the most common symptoms (16.2%).

    PMID 41998668 · one of two readings recorded this

  • Gastrointestinal decontamination performed

    n = 197

    Gastrointestinal decontamination was performed in 81.6% of patients, and 14.7% received N-acetylcysteine therapy.

    PMID 41998668 · one of two readings recorded this

  • Intent of ingestion by sex (accidental more common in boys, intentional in girls)

    p = 0.001, n = 197

    Accidental ingestion was more common in boys, while intentional ingestion predominated in girls (p < 0.001)

    PMID 41998668 · one of two readings recorded this

  • Intentional ingestion proportion

    n = 197

    Accidental ingestion accounted for 49.2% of cases, whereas 50.8% were intentional.

    PMID 41998668 · one of two readings recorded this

  • N-acetylcysteine therapy received

    n = 197

    Gastrointestinal decontamination was performed in 81.6% of patients, and 14.7% received N-acetylcysteine therapy.

    PMID 41998668 · one of two readings recorded this

  • Nausea and vomiting at presentation

    n = 197

    At presentation, 68.5% of patients were asymptomatic, and nausea and vomiting were the most common symptoms (16.2%).

    PMID 41998668 · one of two readings recorded this

  • Paracetamol ingested alone

    n = 197

    Paracetamol was ingested alone in 42.1% of patients and in combination with other drugs in 57.9%.

    PMID 41998668 · one of two readings recorded this

  • Paracetamol ingested in combination with other drugs

    n = 197

    Paracetamol was ingested alone in 42.1% of patients and in combination with other drugs in 57.9%.

    PMID 41998668 · one of two readings recorded this

  • Serum paracetamol above Rumack-Matthew treatment line

    n = 197

    Only 2 patients (1.0%) had serum paracetamol levels above the treatment line on the Rumack–Matthew nomogram.

    PMID 41998668 · one of two readings recorded this

  • Serum paracetamol above treatment threshold among those measured

    n = 137

    Serum paracetamol levels were measured in 137 patients (69.5%); of these, 2 (1.5%) had levels above the Rumack–Matthew treatment threshold.

    PMID 41998668 · one of two readings recorded this

  • Time to hospital admission

    n = 197

    The mean time to hospital admission was 3.1 ± 3.9 hours.

    PMID 41998668 · one of two readings recorded this

  • ADHD diagnosis or ADHD-specific medication prescription in offspring, sibling-matched Cox model

    no effect, aHR 1.01; 95% CI 0.93-1.08

    Not recorded as a finding: no outcome node for ADHD diagnosis in offspring

    In the sibling-matched analyses, prenatal paracetamol exposure was not associated with the risk of ASD (adjusted hazard ratio [aHR], 1.00; 95% CI, 0.91-1.11) or ADHD (aHR, 1.01; 95% CI, 0.93-1.08).

    PMID 42371637 · both readings recorded this

  • ADHD risk

    no effect, n = 97285

    or ADHD (aHR, 1.01; 95% CI, 0.93-1.08)

    PMID 42371637 · one of two readings recorded this

  • ADHD risk

    increases

    and ADHD (HR, 1.24; 95% CI, 1.20-1.28)

    PMID 42371637 · one of two readings recorded this

  • Autism spectrum disorder risk

    no effect, n = 124333

    prenatal paracetamol exposure was not associated with the risk of ASD (adjusted hazard ratio [aHR], 1.00; 95% CI, 0.91-1.11)

    PMID 42371637 · one of two readings recorded this

  • Autism spectrum disorder risk

    increases

    negative control analyses of prepregnancy exposure for ASD (HR, 1.12; 95% CI, 1.08-1.17)

    PMID 42371637 · one of two readings recorded this

  • Prenatal paracetamol exposure prevalence in initial cohort

    n = 708020

    From an initial cohort of 708 020 mother-child pairs (approximately 43.3% with prenatally paracetamol exposure)

    PMID 42371637 · one of two readings recorded this

  • ADHD diagnosis (cord plasma acetaminophen biomarker dose-response)

    increases, odds of ADHD diagnosis increased 2.25 to 2.86 times

    A strong dose-response relationship between fetal acetaminophen exposure, measured by cord plasma biomarkers, and ADHD diagnoses was observed, increasing the odds of an ADHD diagnosis in 2.25 to 2.86 times.

    PMID 42500177 · one of two readings recorded this

  • ADHD diagnosis

    increases, odds increased 2.25 to 2.86 times (cord plasma biomarker dose-response)

    A strong dose-response relationship between fetal acetaminophen exposure, measured by cord plasma biomarkers, and ADHD diagnoses was observed, increasing the odds of an ADHD diagnosis in 2.25 to 2.86 times.

    PMID 42500177 · one of two readings recorded this

  • ADHD symptoms

    increases, RR 1.45, 95% CI 1.18 to 1.78

    Self-reported maternal acetaminophen use and an increased risk of ADHD symptoms in children (RR 1.45, 95% CI 1.18 to 1.78) was also noted.

    PMID 42500177 · one of two readings recorded this

  • ASD symptoms presence

    no effect, OR 1.16, 95% CI 0.94 to 1.43, p= 0.1719, I2 = 0%

    A higher risk of presenting ASD symptoms by 16% was observed, albeit not statistically significant (OR 1.16, 95% CI 0.94 to 1.43, p= 0.1719, I2 = 0%) and with no substantial heterogeneity in the sensitivity analysis (Supplemental material: Figure S2).

    PMID 42500177 · one of two readings recorded this

  • Autism spectrum disorder (ASD) diagnosis and ASD symptoms in offspring, pooled odds ratio across observational cohort studies of prenatal acetaminophen exposure

    increases, OR 1.18, 95% CI 1.15 to 1.32, p <0.0001, I2 = 45.9%

    Not recorded as a finding: this platform holds no node for the endpoint

    The pooled results showed that acetaminophen use during pregnancy increased the risk of ASD diagnosis by 18% (OR 1.18, 95% CI 1.15 to 1.32, p <0.0001; I2 = 45.9%).

    PMID 42500177 · one of two readings recorded this

  • Autism Spectrum Disorder (ASD) diagnosis in offspring, pooled odds ratio across cohort studies

    increases, OR 1.18, 95% CI 1.15 to 1.32, p <0.0001; I2 = 45.9%

    Not recorded as a finding: this platform holds no node for the endpoint

    The pooled results showed that acetaminophen use during pregnancy increased the risk of ASD diagnosis by 18% (OR 1.18, 95% CI 1.15 to 1.32, p <0.0001; I2 = 45.9%).

    PMID 42500177 · one of two readings recorded this

  • Autism spectrum disorder (ASD) diagnosis

    increases, OR 1.18, 95% CI 1.15 to 1.32, p <0.0001, I2 = 45.9%

    The pooled results showed that acetaminophen use during pregnancy increased the risk of ASD diagnosis by 18% (OR 1.18, 95% CI 1.15 to 1.32, p <0.0001; I2 = 45.9%).

    PMID 42500177 · both readings recorded this

  • Autism spectrum symptoms (CAST or similar screening scores)

    increases, OR 1.16, 95% CI 0.94 to 1.43, p = 0.1719, I2 = 0% (not statistically significant)

    A higher risk of presenting ASD symptoms by 16% was observed, albeit not statistically significant (OR 1.16, 95% CI 0.94 to 1.43, p= 0.1719, I2 = 0%) and with no substantial heterogeneity in the sensitivity analysis (Supplemental material: Figure S2).

    PMID 42500177 · one of two readings recorded this